TCGA profiling of muscle invasive bladder cancers reveals frequent mutations in cell cycle regulators. Cell cycle inhibitors targeting cyclin dependent kinases 4 and 6 (CDK4/6) have recently shown clinical potential as targeted therapies in various tumor types including sarcomas, breast cancer, melanomas, and hematologic malignancies. Previous studies have shown that functional RB1 is required for cell cycle arrest by CDK4/6 inhibitors in virtually all cancer types. However, these preclinical studies focus on short-term drug assessment. It is not known how cells may evolve in response to long-term treatment with CDK4/6 inhibitors. In this study, we profiled a panel of 33 bladder cancer cells by targeted DNA sequencing, array comparative genomic hybridization, and transcriptome sequencing to identify cell lines with genetic alterations in clinically relevant cell-cycle related genes. Our analysis identified previously unreported RB1 mutations in commercially available cell lines studied in large-scale profiling efforts. A subset of these cell lines was screened for sensitivity to the CDK4/6 inhibitors palbociclib (PD-0332991, Pfizer) and ribociclib (LEE011, Novartis). As in other tumor types, sensitivity to CDK4/6 inhibition was increased in cells with genetic loss of CDKN2A, while cells with deleterious alterations in RB1 were intrinsically resistant regardless of CDKN2A status. To identify the mechanisms of acquired resistance to CDK4/6 inhibitors, the palbociclib-sensitive bladder cancer cell line HCV29 was cultured under continuous drug treatment. After five months, we were able to identify sublines with reduced drug sensitivity. Whole exome sequencing revealed de novo loss-of-function mutations in RB1 in four sublines coupled with whole chromosome loss. Our results confirm previous findings that intact RB1 is necessary for response to CDK4/6 inhibition in bladder cancer cells, but sensitive cells can gain novel genetic alterations that evade drug-induced cell cycle arrest.
|Commitee:||Chan, Timothy, Sander, Chris, White, Richard|
|School:||Weill Medical College of Cornell University|
|Department:||Cell & Developmental Biology|
|School Location:||United States -- New York|
|Source:||DAI-B 78/12(E), Dissertation Abstracts International|
|Subjects:||Biology, Genetics, Bioinformatics|
|Keywords:||Bladder, CDKN2A, Palbociclib, RB1, RNA-Seq, Targeted sequencing|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be